Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for AbCellera Biologics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.59) for the year, down from their previous forecast of ($0.56). The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for AbCellera Biologics' Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.63) EPS.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 13.40% and a negative net margin of 463.77%. The business had revenue of $6.51 million during the quarter, compared to analysts' expectations of $8.95 million. During the same period in the prior year, the company posted ($0.10) earnings per share.

Several other research analysts have also weighed in on the stock. Stifel Nicolaus reiterated a "buy" rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday. KeyCorp reaffirmed an "overweight" rating and issued a $5.00 price target (down from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th. Finally, Benchmark reissued a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday.

AbCellera Biologics Stock Performance

Shares of NASDAQ ABCL traded down $0.04 during mid-day trading on Thursday, reaching $2.72. The company had a trading volume of 2,347,285 shares, compared to its average volume of 1,635,361. The company has a market capitalization of $801.49 million, a price-to-earnings ratio of -4.54 and a beta of 0.35. The stock has a fifty day moving average of $2.63 and a two-hundred day moving average of $3.05. AbCellera Biologics has a 12-month low of $2.34 and a 12-month high of $6.05.

Institutional Trading of AbCellera Biologics

Several large investors have recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI bought a new position in shares of AbCellera Biologics during the 3rd quarter valued at $26,000. Evergreen Capital Management LLC acquired a new position in AbCellera Biologics during the second quarter worth $32,000. NBC Securities Inc. raised its holdings in AbCellera Biologics by 56.0% during the third quarter. NBC Securities Inc. now owns 11,420 shares of the company's stock valued at $29,000 after buying an additional 4,100 shares in the last quarter. Ballentine Partners LLC acquired a new stake in shares of AbCellera Biologics in the third quarter worth about $54,000. Finally, B. Riley Wealth Advisors Inc. boosted its stake in shares of AbCellera Biologics by 104.8% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company's stock worth $64,000 after acquiring an additional 11,000 shares in the last quarter. 61.42% of the stock is owned by institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.